IQVIA (NYSE:IQV) Earns Outperform Rating from Analysts at Royal Bank Of Canada

Royal Bank Of Canada assumed coverage on shares of IQVIA (NYSE:IQV) in a research report report published on Tuesday morning, MarketBeat reports. The firm issued an outperform rating and a $221.00 price objective on the medical research company’s stock.

Other equities research analysts have also issued research reports about the company. TD Cowen lifted their price target on IQVIA from $215.00 to $245.00 and gave the stock a “hold” rating in a research note on Thursday, January 22nd. UBS Group cut their target price on IQVIA from $280.00 to $240.00 and set a “buy” rating for the company in a research note on Friday, February 6th. Citigroup decreased their price target on shares of IQVIA from $230.00 to $200.00 and set a “neutral” rating on the stock in a research note on Friday, February 6th. BMO Capital Markets set a $250.00 price objective on shares of IQVIA in a research note on Friday, February 6th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of IQVIA in a research report on Thursday, January 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, IQVIA presently has an average rating of “Moderate Buy” and an average target price of $231.13.

IQVIA Stock Up 0.3%

Shares of NYSE IQV opened at $178.50 on Tuesday. The business has a 50-day moving average of $208.27 and a 200-day moving average of $207.49. The firm has a market capitalization of $30.29 billion, a price-to-earnings ratio of 22.71, a PEG ratio of 1.71 and a beta of 1.39. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.09. IQVIA has a 12 month low of $134.65 and a 12 month high of $247.04.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Thursday, February 5th. The medical research company reported $3.42 EPS for the quarter, topping analysts’ consensus estimates of $3.40 by $0.02. The business had revenue of $4.36 billion during the quarter, compared to analysts’ expectations of $4.24 billion. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The business’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned $3.12 EPS. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. Sell-side analysts expect that IQVIA will post 10.84 earnings per share for the current fiscal year.

Hedge Funds Weigh In On IQVIA

Several hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. raised its position in IQVIA by 0.8% during the 4th quarter. Vanguard Group Inc. now owns 19,650,532 shares of the medical research company’s stock valued at $4,429,426,000 after purchasing an additional 159,899 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of IQVIA by 0.6% during the fourth quarter. Geode Capital Management LLC now owns 4,374,971 shares of the medical research company’s stock valued at $982,272,000 after acquiring an additional 24,453 shares in the last quarter. Boston Partners lifted its stake in IQVIA by 14.9% in the fourth quarter. Boston Partners now owns 4,087,380 shares of the medical research company’s stock worth $923,276,000 after acquiring an additional 530,672 shares during the period. JPMorgan Chase & Co. boosted its holdings in IQVIA by 16.2% in the fourth quarter. JPMorgan Chase & Co. now owns 3,799,600 shares of the medical research company’s stock valued at $856,468,000 after acquiring an additional 528,753 shares in the last quarter. Finally, Alliancebernstein L.P. increased its position in IQVIA by 1.2% during the 3rd quarter. Alliancebernstein L.P. now owns 3,597,572 shares of the medical research company’s stock valued at $683,323,000 after purchasing an additional 41,643 shares during the period. 89.62% of the stock is owned by institutional investors.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.